Empo Health, today announced the commercialization of its innovative solution for diabetic foot ulcer (DFU) management, on the heels of its most recent $7 million fundraising round. The round was led by Story Ventures, with participation from VTC Ventures, alongside existing investors including Ulu Ventures, SeaX Ventures, Arben Ventures, and Gaingels. This funding brings Empo's capital raised to-date to $15 million.

Empo Health® is a healthcare technology company focused on improving patient outcomes with novel in-home health monitoring devices. The company has developed the FDA-listed Empo® Footprint and HIPAA-compliant Empo® Remote Health Link for monitoring diabetic foot complications. .